Chief Scientific Officer · Enliven Therapeutics, Inc. (ELVN)

Joseph Lyssikatos

A named executive officer of Enliven Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,011,320

Salary $436,502Stock awards $0

FY2022: $535,770

3rd of 4 named executive officers at Enliven Therapeutics by FY2023 total.

4 named officers on file for Enliven Therapeutics, FY2023

Joseph Lyssikatos’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Enliven Therapeutics’s whole pay program stands against its peers

  • Enliven Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELVN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joseph Lyssikatos’s full pay file as a PDF — free

More than this page: up to 10 years of Joseph’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joseph Lyssikatos compensation by year

Enliven Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Enliven Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$350,000$436,502
Bonus$0$0
Stock awards$0$0
Option awards$27,770$3,378,647
Non-equity incentive$156,000$193,600
Pension and deferred compensation$0$0
All other$2,000$2,571
Total$535,770$4,011,320

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Enliven Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001193125-24-117969, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Enliven Therapeutics, Inc. filed document, accession 0001193125-24-117969. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$536K
$4.0M
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option22,133—$2.48
Option206,000—$22.75
Option28,714—$1.12

Per the Outstanding Equity Awards at Fiscal Year-End table in Enliven Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

52 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-12Grant or award—18,750$0.0018,750
2026-02-12Grant or award derivative—112,500$0.00112,500
2026-02-06Sale10b5-15,000$29.04740,188
2026-01-20Sale10b5-114,509$26.90745,188
2026-01-20Sale10b5-15,491$26.37759,697
2026-01-09Sale10b5-141,198$24.90815,188
2026-01-09Sale10b5-150,000$29.13765,188
2026-01-08Sale10b5-17,500$20.13890,188

The 8 most recent of 52 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Enliven Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Sam KintzPresident and Chief Executive Officer$8,279,751
Helen CollinsChief Medical Officer$4,064,839
Joseph Lyssikatos · this pageChief Scientific Officer$4,011,320
Rahul BallalFormer President and Chief Executive Officer$1,865,809

Board service

Enliven Therapeutics board · FY2023

How this board is paid

Company policy: Enliven Therapeutics pays directors a $35,000 cash retainer and $250,000 in Options. As stated in Enliven Therapeutics's FY2023 proxy.

The full Enliven Therapeutics compensation record

free company brief

This page is one person within Enliven Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Enliven Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Lyssikatos's compensation dossier · One-time report. No refunds.